Index

Note: Page numbers of article titles are in boldface type.

A

A Crohn Disease Clinical Trial Evaluating Infliximab in a New Long-term Treatment Regimen (ACCENT), 7, 9, 25
Abscess, of anal glands, 20, 22, 28
Absorptive carbon, for fistulas, 26
ACCENT (A Crohn Disease Clinical Trial Evaluating Infliximab in a New Long-term Treatment Regimen), 7, 9
Adalimumab
   for fistulas, 24–25
   for induction therapy, 3
   for top-down therapy, 9
   in pregnancy, 59, 64–65
   infection risks from, 119–120
   lymphoma risks from, 104
   mucosal healing with, 7–8
Alendronate, in pregnancy, 59
American Gastroenterological Association, fistula classification of, 21–22
5-Aminosalicylates. See also specific agents, eg, Mesalamine; Sulfasalazine.
   for pediatric patients, 43–44, 47
   in pregnancy, 58–60
   lymphoma risks from, 96
   postoperative, 182
Anal glands, abscess of, 20, 22, 28
Antibiotics. See also specific antibiotics.
   Clostridium difficile infections due to, 138
   for fistulas, 23
   in pregnancy, 60
Antichitobioside carbohydrate antibodies, 157–158
Antilaminaribioside carbohydrate antibodies, 157–159
Antimannobioside carbohydrate antibodies, 157–158
Antineutrophil cytoplasmic antibodies, in inflammatory bowel disease, 156–160
Anti-Saccharomyces cerevisiae antibodies, 157–160
Aspergillosis, from medications, 125
AST-120, for fistulas, 26
Autoimmune pouchopathy, 83
Azathioprine
   for fistulas, 23
   for induction therapy, 3–4
   for pediatric patients, 44–45
   for top-down therapy, 9
   in pregnancy, 59, 61–62
   infection risks from, 117–118
   lymphoma risks from, 98–101
Azathioprine (continued)
mucosal healing with, 7
postoperative, 183–184

B
Balloon enteroscopy, 167–168
Balsalazide, in pregnancy, 58–60
*Bifidobacterium*, for pouchitis, 82–83
Biologic agents. See also specific agents.
  for pediatric patients, 45–46
  in pregnancy, 63–65
  postoperative, 184
Biomarkers, for inflammatory bowel disease, 156–161
Bismuth carbomer enemas, for pouchitis, 84
Breastfeeding, medications and, 59–65
Budesonide
  for induction therapy, 3
  for pouchitis, 83
  in pregnancy, 59
  infection risks from, 117
  mucosal healing with, 7
  postoperative, 183

C
Calprotectin, 79–80, 169
Candidiasis, from medications, 125
Capsule endoscopy, 166–167
Carbohydrate antibodies, 157–158
CBir1flagellin antibodies, 157
Cecum, resection of, postoperative management after, 179–188
Cell cytotoxicity test, for *Clostridium difficile*, 141
Certolizumab pegol
  for fistulas, 25
  for induction therapy, 3
  for top-down therapy, 9
  in pregnancy, 59, 65
  infection risks from, 119–120
  lymphoma risks from, 104–105
  mucosal healing with, 7
CHARM (Crohn Trial of the Fully Human Antibody Adalimumab for Remission
  Maintenance) trial, 9, 25
Chitobioside carbohydrate, antibodies to, 157–159
Cholestyramine, for *Clostridium difficile* infections, 145
Ciprofloxacin
  for fistulas, 23
  for pouchitis, 83–84
  in pregnancy, 59–60
*Clostridium difficile* infections, 135–153
  BI/NAP/027 strain of, 136
  clinical features of, 139–140
  diagnosis of, 140–141
enteritis in, 147
from medications, 124
outcomes of, 141–142
pathogenesis of, 136
pouchitis in, 147–148
prevalence of, 136–138
prevention of, 146–147
recurrent, 146
risk factors for, 138–139
severe, 145–146
treatment of, 142–148
Coccidioidomycosis, from medications, 125
Colectomy
for *Clostridium difficile* infections, 141, 145
pouchitis after, 75–92
Colestipol, for *Clostridium difficile* infections, 145
Colitis, *Clostridium difficile*, 135–153
Colonoscopy
for *Clostridium difficile* infections, 140
for surveillance, 181
Computed tomography, 22, 162–163
Corticosteroids
for induction therapy, 3–5
for pediatric patients, 41–42
for top-down therapy, 10
in pregnancy, 59–61
infection risks from, 116–117
lymphoma risks from, 96
C-reactive protein, 160–161
Crohn disease
clinical presentation of, 41
diagnosis of, 155–178
epidemiology of, 36–37
fertility issues in, 53, 55–56
fistulizing
anatomic considerations in, 20–22
evaluation of, 22
pathogenesis of, 20–22
treatment of, 23–30
gender differences in, 36
genetic factors in, 40–41, 53
in pediatric patients, 35–52
in pregnancy, 53–73
location of, 38
natural history of, 180
of pouch, 80–81
phenotypes of, 39–40
postoperative, 185–186
prognosis for, 155–178
recurrent, 155–178
surveillance of, 180–181
Crohn (continued)

treatment of

*Clostridium difficile* infections in, 135–153
combination, 120–121
current approaches to, 3–4
fistulizing, 19–34
in pediatric patients, 41–47
in pregnancy, 58–66
induction, 3–4
lymphoma risks in, 46–47, 93–113
postoperative management of, 179–188
response to, 5–6
safety profile of, 115–133
selection of, 2
top-down versus step-up, 1–10, 28–30

Crohn disease, treatment of, top-down, 8–10
Crohn Trial of the Fully Human Antibody Adalimumab for Remission Maintenance
(CHARM) trial, 9, 25

Cryptococcosis, from medications, 125

Cuffitis, 80–81

Culture, stool, for *Clostridium difficile*, 140–141

Cyclosporine

for acute disease, 5
for fistulas, 24
in pregnancy, 59, 62–63
infection risks from, 121–122
lymphoma risks from, 96–97

Cytokines, in pouchitis, 77

Cytomegalovirus infections, from medications, 126

D

Diarhea, in *Clostridium difficile* infections, 139
Diverting ostomy, for fistulas, 28

E

ENACT trials, 26
Endoscopic ultrasound, for fistulas, 22, 26–27
Endoscopy, 166–168
for *Clostridium difficile* infections, 140
for pouchitis, 79
for surveillance, 181
Enemas, for pouchitis, 84
Enteral feeding, for pediatric patients, 42–43
Enteritis, *Clostridium difficile*, 147

Enterography

computed tomography, 162–163
magnetic resonance, 163–164

Environmental factors, in *Clostridium difficile* infections, 138

Enzyme-linked immunosorbent assay

for antineutrophil cytoplasmic antibodies, 156
for *Clostridium difficile*, 140–141
Escherichia coli, porin C protein of, 157
Examination under anesthesia, for fistulas, 27
Extrasphincteric fistulas, 21

F
Fecal diversion, for fistulas, 28
Fecal markers, of inflammation, 168–170
Feces, infusion of, for Clostridium difficile infections, 146
Fertility, 53, 55–56
Fibrin glue, for fistulas, 27
Fish oil supplements, in pregnancy, 59, 65
Fistulas, in Crohn disease, 19–34
  anatomic considerations in, 20–22
  assessment of, 22
  classification of, 21–22
  incidence of, 19–20
  pathogenesis of, 20–22
  rectovaginal, 28
  treatment of, 23–30
Fistulography, for fistulas, 22
Fistulotomy, 27
Fluoroquinolones, in pregnancy, 60
Fluoroscopy, 161–162
Fungal infections, from medications, 124–125

G
Gender differences, 36
Genetic factors, 40–41, 53, 78
Glucocorticosteroids. See Corticosteroids.
Glue, fibrin, for fistulas, 27
Glycan antibodies, 157–158
Growth deficiency, in pediatric patients, 41, 46

H
Hepatitis B, from medications, 125
Hepatitis C, from medications, 125
Histoplasmosis, from medications, 125
Human immunodeficiency virus infection, from medications, 126
Human papillomavirus infections, from medications, 126

I
Ileal pouch-anal anastomosis procedure, pouchitis after, 75–92
Ileum, resection of, postoperative management after, 179–188
Immunoglobulin, intravenous, for Clostridium difficile infections, 146
Immunomodulators
  for fistulas, 23
  for pediatric patients, 44–45
  in pregnancy, 61–63
  infection risks from, 117–119
Immunosuppression

*Clostridium difficile* infections in, 138
lymphoma in, 95–96

**Infection risks, 115–133**

- bacterial, 123–124
- from combination therapy, 120–121
- from corticosteroids, 116–117
- from cyclosporine, 121–122
- from immunomodulators, 117–119
- from natalizumab, 122
- from tumor necrosis factor inhibitors, 119–120
- fungal, 124–125
- pharmacoepidemiology of, 116
- postoperative, 122–123
- vaccination recommendations for, 126
- viral, 125–126

**Infertility, 53, 55–56**

**Inflammation, fecal markers of, 168–170**

**Inflammatory bowel disease**

- diagnosis of, 155–178
- in pediatric patients, 35–52
- in pregnancy, 53–73
- prognosis for, 155–178
- safety database for, 63–64
- treatment of
  - *Clostridium difficile* infections in, 135–153
  - fistulizing, 19–34
  - lymphoma risks in, 46–47, 93–113
  - postoperative management of, 179–188
  - pouchitis after, 75–92, 147–148
  - response to, 5–6
  - safety profile of, 115–133
  - top-down versus step-up, 1–18, 28–30

**Infliximab**

- for fistulas, 24–26, 28
- for induction therapy, 3–5
- for pediatric patients, 45–46
- for pouchitis, 84
- for top-down therapy, 9–11
- in pregnancy, 59, 63–64
- infection risks from, 119–123
- lymphoma risks from, 101–104
- mucosal healing with, 7–8
- postoperative, 184
- response to, 6

**Intersphincteric fistulas, 21**

**Irritable pouch syndrome, 81**

**L**

*Lactobacillus rhamnosus* GG, for pouchitis, 82–83
Lactoferrin, 79–80, 169–170
Laminaribioside carbohydrate, antibodies to, 157–158
Levofloxacin, in pregnancy, 60
Listeria monocytogenes infections, from medications, 124
Lymphoma risks, 93–113
  from aminosalicylates, 96
  from azathioprine, 98–101
  from corticosteroids, 96
  from cyclosporine, 96–97
  from immunosuppressive agents, 95–96
  from 6-mercaptopurine, 98–101
  from methotrexate, 97–98
  from tumor necrosis factor inhibitors, 101–105
hepatosplenic T cell, 105
in pediatric patients, 46–47
independent of medications, 93–95
versus benefits of treatment, 105–106

M
Magnetic resonance imaging, 22, 27, 163–164
Mannobioside carbohydrate, antibodies to, 157–158
6-Mercaptopurine
  for fistulas, 23
  for induction therapy, 3–4
  for pediatric patients, 44–45
  for top-down therapy, 9
  in pregnancy, 59, 61–62
  infection risks from, 117–118
  lymphoma risks from, 98–101
  mucosal healing with, 7–8
  postoperative, 183–184
Mesalamine
  for induction therapy, 5
  in pregnancy, 58–60
  mucosal healing with, 7
  postoperative, 182
  response to, 6
Methotrexate
  for induction therapy, 3–4
  for pediatric patients, 44–45
  in pregnancy, 59, 61
  infection risks from, 118–119, 121
  lymphoma risks from, 97–98
  mucosal healing with, 7
Metronidazole
  for Clostridium difficile infections, 142–143, 146
  for fistulas, 23
  for pouchitis, 84
  in pregnancy, 59–60
  postoperative, 183
Mucosal healing, as end point in treatment, 6–8
N
Natalizumab
  for fistulas, 26
  for induction therapy, 3
  infection risks from, 122
NOD2 gene mutations, 40
Norfloxacin, in pregnancy, 60
Nutritional therapy, for pediatric patients, 42–43

O
Olsalazine, in pregnancy, 58–60
OmpC antibody, 157
Organization for Teratology Information Specialists (OTIS), 64–65
Omidazole, postoperative, 183

P
Pancreatic antibodies, 157
Paneth cells, in pouchitis, 77
Parks classification, of fistulas, 20
Pediatric Crohn Disease Activity Index, 46–47
Pediatric patients, inflammatory bowel disease in, 35–52
  clinical presentation of, 41
  epidemiology of, 36–40
  gender differences in, 36
  genetic factors in, 40–41
  location of, 38
  phenotypes of, 39–40
  treatment of, 41–47
PEGylated antibody, Fragment Evaluation in Crohn Diseases Safety and Efficacy (PRECiSE) study, 5, 9, 25
Perforation, colonic, in Clostridium difficile infections, 141
Peritonitis, in Clostridium difficile infections, 141
Pneumocystis carinii pneumonia, from medications, 124
Polypectomy, for pouchitis, 84
Porin C antibody, 157
Positron emission tomography, 166
Pouchitis, 75–92
  acute, 81
  autoimmune, 83
  classification of, 81–82
  Clostridium difficile, 147–148
  diagnosis of, 79–80
  differential diagnosis of, 80–81
  epidemiology of, 75
  etiology of, 76–78
  laboratory tests for, 79–80
  natural history of, 77–78
  pathogenesis of, 76–78
prophylaxis of, 82
refractory, 81, 84
risk factors for, 78–79
treatment of, 82–85
PRECiSE (PEGylated antibody, Fragment Evaluation in Crohn Diseases Safety and Efficacy) study, 5, 9, 25
Prednisone
for pediatric patients, 47
for top-down therapy, 8
Pregnancy, inflammatory bowel disease in, 53–73
disease activity in, 57
fertility and, 53, 55–56
labor and delivery concerns in, 57–58
offspring inheritance and, 53
patient questions about, 54
pregnancy outcomes in, 56–57
treatment of, 58–65
Probiotics
for Clostridium difficile infections, 144, 146
for pouchitis, 82–83
Protectomy, for fistulas, 28
Pseudomembranes, in Clostridium difficile infections, 140
Pseudomonas fluorescens, antibodies to, 157
PSMG1 gene mutations, 40

R
Radiography, for Clostridium difficile infections, 140
REACH trial, 9
Rectovaginal fistulas, 28
Rifaximin
for Clostridium difficile infections, 144–146
for pouchitis, 84
in pregnancy, 59
Risedronate, in pregnancy, 59

S
Saccharomyces cerevisiae antibodies, 157–160
Serologic biomarkers, for inflammatory bowel disease, 156–161
Seton placement, for fistulas, 27
Sexual function, 53, 55–56
Small bowel capsule endoscopy, 166–167
Small intestine, resection of, postoperative management after, 179–188
SONIC (Study of Biologic and Immunomodulator Naive Patients in Crohn Disease) study, 6, 10
Stool culture, for Clostridium difficile, 140–141
Streptococcus salivarius, for pouchitis, 82
Study of Biologic and Immunomodulator Naive Patients in Crohn Disease (SONIC) study, 6, 10
Sulfasalazine
- for induction therapy, 5
- in pregnancy, 58–60
- postoperative, 183

Superficial fistulas, 21

Suprasphincteric fistulas, 21

Tacrolimus
- for fistulas, 24
- in pregnancy, 59, 62–63

Teicoplanin, for *Clostridium difficile* infections, 145

Thalidomide, in pregnancy, 59, 63

Therapy, Resource, Evaluation, and Assessment Tool (TREAT) Registry, 63–64, 116, 119–120

TNFRSF6B gene mutations, 40

Toll-like receptors, in pouchitis, 77

Toxic megacolon, in *Clostridium difficile* infections, 141

Toxins, of *Clostridium difficile*, 136, 140–141

Trans-sphincteric fistulas, 21

TREAT (Therapy, Resource, Evaluation, and Assessment Tool) registry, 63–64, 116, 119–120

Tuberculosis, from medications, 123–124

Tumor necrosis factor antagonists. See also specific substances.
- for fistulas, 24–26
- infection risks from, 119–120, 123–124
- lymphoma risks from, 101–105

Ulcerative colitis
- clinical presentation of, 41
- diagnosis of, 155–178
- epidemiology of, 36–37
- fertility issues in, 53, 55–56
- gender differences in, 36
- genetic factors in, 40–41, 53
- in pediatric patients, 35–52
- in pregnancy, 53–73
- location of, 38
- natural history of, 4
- phenotypes of, 39–40
- prognosis for, 155–178
- treatment of
  - *Clostridium difficile* infections in, 135–153
  - current approach to, 4–5
  - in pediatric patients, 41–47
  - in pregnancy, 58–66
  - induction, 5
  - lymphoma risks in, 46–47, 93–113
pouchitis after, 75–92
response to, 5–6
safety profile of, 115–133
top-down versus step-up, 10–11
Ultrasonography, 22, 26–27, 164–166

V
Vaccinations, for infection prevention, 126
Vancomycin, for Clostridium difficile infections, 143–146
Varicella, from medications, 126